Chief Technology Officer and President of ImmunoForge's US branch since January 2021 and previously VP Research & Scientific Affairs at PhaseBio Pharmaceuticals from 2012 - Dec 2020, where I worked to develop and refine the ELP platform that is now the basis of several of ImmunoForge's development candidates. I previously worked on two other half-life extension technologies: albumin fusions at Delta Biotechnology (UK), where I was Head of R&D, and transferrin fusions at BioRexis (acquired by Pfizer in 2007).